• Image courtesy of Dr Kristen Brennand & Dr Fred H. Gage/ Salk Institute for Biological Studies

    human stem cells 2
  • Image courtesy of Dr Yichen Shi and Dr Rick Livesey/ Cambridge Stem Cell Institute

    human stem cells
About EUCelLEX

The European EUCelLEX Project consists in a full examination of the application of the European rules regarding cell banks together with current practices in respect of the therapeutic use of human cells in the different countries concerned. The purpose is to submit the data obtained to the European Commission for it to draw up legislative measures in line with medical advances in this field.
The EUCelLEX project has received funding from the European Union’s FP7 and is coordinated by Emmanuelle RIAL-SEBBAG (Inserm).



Authors: Brooke Ellison
Ellison, B. Curr Stem Cell Rep (2016). doi:10.1007/s40778-016-0063-3

Abstract: As stem cell research moves toward clinical translation and therapeutic application, ethical focus must be broadened to include questions about the interface of science and society. Among these societal questions is how to conduct this research in a socially just manner, as well as how and why stem cell research ought to be used as a vehicle to advance social justice imperatives. This article provides an overview of justice as a social and philosophical construct, and how it can be incorporated into science discussions. This review then addresses prominent social justice challenges, especially as they relate to biomedical research and healthcare, and how stem cell research might be a mechanism to reduce the burden of these injustices. Finally, this article concludes with ways to structure our ethical thinking and scientific debate in order to determine if stem cell research is being pursued in a socially just manner.

To read this article

The third Policy Briefing on regenerative medicine from REGenableMED Project is focused on the challenges of scale-up/manufacture of cell therapies.

REGenableMED Project is holding a meeting with UK Members of Parliament on November 8th about the results of their work.

More information on the project can be found here.

We are pleased to share the final conference programme for the EUCelLEX Final International Conference and EAHL joint workshop.

To download a PDF version of the final programme click here.

Authors: Mohamed Abou-El-Enein, Ahmed Elsanhoury, Petra Reinke.

Article in Cell Stem Cell, Volume 19, Issue 3, 1 September 2016, Pages 293–297. (doi: 10.1016/j.stem.2016.08.012)

While advanced therapy medicinal products offer great clinical promise, most EU-approved products have not achieved satisfactory commercial performance. Here we highlight a number of issues that prevent current products from obtaining commercial success and pitfalls that developers must overcome in future product development.

The European Medicines Agency (EMA) published a report from a multi-stakeholder expert meeting held on 27 May 2016 to explore possible ways to foster the development of ATMPs in Europe and expand patients’ access to these new treatments.

To view the press release click here.

To view the PDF click here.